| Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed M Feldmann, RN Maini, JN Woody, ST Holgate, G Winter, M Rowland, ... The Lancet 395 (10234), 1407-1409, 2020 | 619 | 2020 |
| Therapeutic clearance of amyloid by antibodies to serum amyloid P component DB Richards, LM Cookson, AC Berges, SV Barton, T Lane, JM Ritter, ... New England Journal of Medicine 373 (12), 1106-1114, 2015 | 398 | 2015 |
| Activation of peroxisome proliferator–activated receptor (PPAR) δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid … U Risérus, D Sprecher, T Johnson, E Olson, S Hirschberg, A Liu, Z Fang, ... Diabetes 57 (2), 332-339, 2008 | 359 | 2008 |
| Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial LM Yu, M Bafadhel, J Dorward, G Hayward, BR Saville, O Gbinigie, ... The Lancet 398 (10303), 843-855, 2021 | 284 | 2021 |
| Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform … CC Butler, FDR Hobbs, OA Gbinigie, NM Rahman, G Hayward, ... The Lancet 401 (10373), 281-293, 2023 | 269 | 2023 |
| Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study VS Hegade, SFW Kendrick, RL Dobbins, SR Miller, D Thompson, ... The Lancet 389 (10074), 1114-1123, 2017 | 202 | 2017 |
| Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma D Singh, D Richards, RG Knowles, S Schwartz, A Woodcock, S Langley, ... American journal of respiratory and critical care medicine 176 (10), 988-993, 2007 | 165 | 2007 |
| Drug discovery and development: technology in transition RG Hill, D Richards Elsevier, 2021 | 157 | 2021 |
| Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment PC Robinson, D Richards, HL Tanner, M Feldmann The Lancet Rheumatology 2 (11), e653-e655, 2020 | 137 | 2020 |
| Medical students in general practice: how do patients feel? F Cooke, G Galasko, V Ramrakha, D Richards, A Rose, J Watkins British Journal of General Practice 46 (407), 361-362, 1996 | 137 | 1996 |
| COVID-19 therapeutics: Challenges and directions for the future PC Robinson, DFL Liew, HL Tanner, JR Grainger, RA Dwek, RB Reisler, ... Proceedings of the National Academy of Sciences 119 (15), e2119893119, 2022 | 126 | 2022 |
| The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19 PC Robinson, DFL Liew, JW Liew, C Monaco, D Richards, S Shivakumar, ... Med 1 (1), 90-102, 2020 | 119 | 2020 |
| Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects H Ziauddeen, SR Chamberlain, PJ Nathan, A Koch, K Maltby, M Bush, ... Molecular psychiatry 18 (12), 1287-1293, 2013 | 110 | 2013 |
| Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis DB Richards, LM Cookson, SV Barton, L Liefaard, T Lane, DF Hutt, ... Science Translational Medicine 10 (422), eaan3128, 2018 | 108 | 2018 |
| Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial TSC Hinks, L Cureton, R Knight, A Wang, JL Cane, VS Barber, J Black, ... The Lancet Respiratory Medicine 9 (10), 1130-1140, 2021 | 88 | 2021 |
| Crowd sourcing in drug discovery M Lessl, JS Bryans, D Richards, K Asadullah Nature Reviews Drug Discovery 10 (4), 241-242, 2011 | 66 | 2011 |
| Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trial DB Richards, P Bareille, EL Lindo, D Quinn, SN Farrow Respiratory medicine 104 (5), 668-674, 2010 | 66 | 2010 |
| Opioid Receptor Modulation of Hedonic Taste Preference and Food Intake: A Single‐Dose Safety, Pharmacokinetic, and Pharmacodynamic Investigation With GSK1521498, a Novel μ … PJ Nathan, BV O'Neill, MA Bush, A Koch, WX Tao, K Maltby, A Napolitano, ... The Journal of Clinical Pharmacology 52 (4), 464-474, 2012 | 58 | 2012 |
| BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial VS Hegade, SFW Kendrick, RL Dobbins, SR Miller, D Richards, J Storey, ... BMC gastroenterology 16, 1-12, 2016 | 44 | 2016 |
| Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive … BA Fisher, T Veenith, D Slade, C Gaskell, M Rowland, T Whitehouse, ... The Lancet Respiratory Medicine 10 (3), 255-266, 2022 | 41 | 2022 |
